Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study.

ABSTRACT: Understanding the immune response to SARS-CoV-2 vaccination in cancer patients remains a critical priority given their immunocompromised status. In this prospective observational study, we evaluated humoral and cellular immunity across three time points-baseline, post-second dose, and post-booster-in 23 breast cancer patients undergoing active treatment. IgG antibody levels showed a significant increase following vaccination, with a 300-fold rise after the second dose and a 2200-fold increase post-booster, indicating a strong humoral response. CD19⁺ B cells also increased significantly, supporting B cell-mediated activation. Although overall T cell frequencies remained stable, we observed a shift toward memory phenotypes, with decreased naïve CD4⁺ and CD8⁺

SUBMITTER: Fernandez-Murga ML 

PROVIDER: S-EPMC12472335 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature